Boston Scientific Announces Enrollment in Taxus OLYMPIC Registry

Boston Scientific has announced the start of enrollment in the world's largest drug-eluting stent registry: the Taxus OLYMPIC registry.

The Taxus OLYMPIC registry plans to enroll more than 30,000 patients at more than 600 centers in the U.S., Europe and other international locations. The registry is designed to collect and analyze "real-world" clinical outcomes data for the Taxus Libert paclitaxel-eluting stent system in the treatment of patients with coronary artery disease.

Boston Scientific said the OLYMPIC registry will enroll patients in five phases, corresponding to the commercial introduction of the Taxus Libert system in different regions of the world. The initial, transitional phase is enrolling patients from a limited number of international markets in which Boston Scientific launched the Taxus Libert system in January. This phase will be followed by enrollment of patients from a broader number of international markets, then from European markets and finally from a two-phase U.S. enrollment.